French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...

Sanofi has signed an agreement to acquire UK-based biotechnology company Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities. The deal also includes additional ...

Vicebio Ltd, a biopharmaceutical company developing novel vaccines, has entered an exclusive, definitive agreement to be ...

Paris-based drugmaker Sanofi is acquiring U,K,-based Vicebio to gain its molecular clamp vaccine technology, with the total ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Respiratory vaccines specialist Vicebio Ltd. is to be acquired by Sanofi SA in a $1.6 billion deal, of which $1.15 billion ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV, ...

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

The US Securities and Exchange Commission has subpoenaed information from Telix, in relation to the company's therapeutic ...

Astra, led by boss Pascal Soriot (pictured), said it is accelerating its expansion in US with an investment that will create ...

“Vicebio’s Molecular Clamp technology introduces a purposefully simple but thoughtful approach to further improve vaccine ...

Health care companies recouped some of their recent losses amid generally strong earnings and deal activity. British drug maker AstraZeneca said it plans to invest $50 billion in the U.S. by 2030, ...